Puma Biotechnology earnings were $24.4M for the trailing 12 months ending Mar 31, 2026, with -35.1% growth year over year. The latest PBYI earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$3.8M, down 127.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, PBYI reported annual earnings of $31.1M, with 2.8% growth.
PBYI past earnings growth
How has PBYI's earnings growth performed historically?
What were Puma Biotechnology's earnings last quarter?
On PBYI's earnings call on Invalid Date, Puma Biotechnology (NASDAQ: PBYI) reported Q1 2026 earnings per share (EPS) of -$0.07, up 216.67% year over year. Total PBYI earnings for the quarter were -$3.75 million. In the same quarter last year, Puma Biotechnology's earnings per share (EPS) was $0.06.
As of the last Puma Biotechnology earnings report, Puma Biotechnology is currently profitable. Puma Biotechnology's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $24.38 million, a 35.94% decrease year over year.
What was PBYI's earnings growth in the past year?
As of Puma Biotechnology's earnings date in Invalid Date, Puma Biotechnology's earnings has grown -35.06% year over year. This is 81.59 percentage points lower than the US Biotechnology industry earnings growth rate of 46.52%. PBYI earnings in the past year totalled $24.38 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.